Syapse
Overview
Oncology real-world evidence company that partners with community health systems to curate longitudinal cancer patient data, offering fit-for-purpose datasets (Syapse Cohorts) and RWE services to life sciences and regulators. Acquired by N-Power Medicine in late 2024 to combine RWD with a prospective clinical research network.
Notable
Long-running research collaboration with the FDA on regulatory use of oncology RWE; raised $204.5M before its acquisition by N-Power Medicine.
Key services
- oncology real-world datasets and cohorts
- health system data curation
- regulatory-grade RWE studies
- mortality-linked oncology outcomes data
Subcategories
Verified Reviews
No verified reviews yet — are you a customer of Syapse? Share your experience in a short, confidential interview.
Share your experienceSources
- https://www.crunchbase.com/organization/syapse
- https://www.globenewswire.com/news-release/2024/05/22/2886726/0/en/Syapse-Expands-Oncology-Real-World-Data-Offerings-with-Introduction-of-Syapse-Cohorts-Essentials.html
- https://www.clinicaltrialsarena.com/news/signal-fda-renews-syapse-collaboration-to-use-real-world-data-in-oncology/